<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364583</url>
  </required_header>
  <id_info>
    <org_study_id>MRAC10.14</org_study_id>
    <nct_id>NCT02364583</nct_id>
  </id_info>
  <brief_title>Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection</brief_title>
  <official_title>Safety, Tolerability and Pilot Efficacy of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Papua New Guinea Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter and Eliza Hall Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Curtin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Papua New Guinea Institute of Medical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study specifically seeks to provide data on the safety, tolerability and pilot efficacy
      of short course, high dose primaquine treatment in Papua New Guinean children aged 5-10
      years, in a cross-sectional study design. Community screened asymptomatic cases and/or cases
      of clinically diagnosed malaria admitted to the out-patient units of the health center, will
      be screened for Glucose-6-phosphate dehydrogenase deficiency (G6PD) and malaria illness by
      rapid diagnostic test and P. vivax infection confirmed by light microscopy. Following
      treatment with artemether-lumefantrine (Coartem), G6PD normal children will be enrolled into
      the study and followed for 2 months. Primaquine treatment will be allocated to study
      participants in a step-wise design; firstly receiving the current 14 day treatment regimen of
      0.5 mg/kg total dose (n=40); secondly, a 7 day treatment regimen receiving a total dose of
      1.0 mg/kg/day; then thirdly, receive 1.0 mg/kg twice daily dose (bd) for a total of 3.5 days,
      should the 7 day treatment prove to be safe and well tolerated. In addition to this
      dose-escalation study, the pharmacokinetic profiles of single doses of 0.5 mg/kg and 1.0
      mg/kg will be determined using an intensive sampling protocol, in children aged 5-10 years.
      The pharmacokinetic profiles obtained by this sub-study will be essential for modeling the
      population pharmacokinetic data obtained from the dose-escalation study. As there is
      currently no data on the safety, tolerability and efficacy of primaquine in children, the
      present study will validate previous observation and contribute to the knowledge of
      primaquine as a treatment for liver stages of Plasmodium vivax infection.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by hemoglobin</measure>
    <time_frame>2 months post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as measured by methemoglobin</measure>
    <time_frame>2 months post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as measured by liver biochemistry</measure>
    <time_frame>2 months post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as measured by symptom questionnaire</measure>
    <time_frame>2 months post baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first or only Plasmodium vivax infection by light microscopy and polymerase chain reaction (PCR)</measure>
    <time_frame>2 months from baseline</time_frame>
    <description>Thick and thin blood films, along with PCR samples, will be collected at time of recruitment and then at any time the participant develops fever within the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first or only clinical Plasmodium vivax episode</measure>
    <time_frame>2 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the rate of incidence of P. vivax relapses in 3.5 or 7 day treatment arm compared to standard 14 day regimen</measure>
    <time_frame>2 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - elimination half-life (t1/2)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - clearance (CL)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - volume of distribution (Vd)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - maximal concentration (Cmax)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - area under the curve (AUC)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Plasmodium Vivax</condition>
  <arm_group>
    <arm_group_label>14 day dose regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mg/kg oral Primaquine administered daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 day dose regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 mg/kg oral Primaquine administered daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.5 day dose regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 mg/kg oral Primaquine administered twice daily (bd) for 3.5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)</description>
    <arm_group_label>14 day dose regimen</arm_group_label>
    <arm_group_label>7 day dose regimen</arm_group_label>
    <arm_group_label>3.5 day dose regimen</arm_group_label>
    <other_name>Primaquine phosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Permanent resident in study area

          -  Absence of history of hypersensitivity reactions to pre-treatment drugs

          -  Positive for P. vivax infections on blood smear or PCR

          -  Normal G6PD enzyme activity

        Exclusion Criteria:

          -  Features of severe malaria

          -  Clinical evidence of nonmalarial illness

          -  Severe malnutrition (weight for age nutritional Z score &lt;60th percentile)

          -  Moderate to severe anemia (Hb &lt;8g/dL)

          -  Permanent disability which prevents or impedes study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inoni Betuela, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PNG Institute of Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivo Mueller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter and Eliza Hall Institute of Medical Research; Centre de Recerca en Salut Internacional de Barcelona (CRESIB)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Kevin Baird, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eijkman-Oxford Clinical Research Unit, Oxford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy ME Davis, FRAC, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Western Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inoni Betuela, MD PhD</last_name>
    <email>inoni.betuela@pngimr.org.pg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivo Mueller, PhD</last_name>
    <phone>+61393452555</phone>
    <email>ivomueller@fastmail.fm</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PNG Institute of Medical Research</name>
      <address>
        <city>Madang</city>
        <state>Madang Province</state>
        <country>Papua New Guinea</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brioni R Moore, PhD</last_name>
      <phone>+61466266334</phone>
      <email>brioni.moore@uwa.edu.au</email>
    </contact>
    <investigator>
      <last_name>Inoni Betuela, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Papua New Guinea</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

